Figure 2.
Outcomes of TCRαβ/CD19-depleted haplo-HSCT and comparison with transplants from HLA-identical sibling and MUD. (A) LFS probability according to the use of TBI in the conditioning regimen (yes, continuous blue line; no, dotted red line). (B) LFS probability according to NK alloreactivity (evaluated using the KIR-KIR-L model of prediction) (yes, dotted red line; no, continuous blue line). (C) Comparison of LFS probability among patients transplanted from different donors (HLA-haploidentical relative [dashed green line], HLA-identical sibling [continuous blue line], and UD [dotted red line]) during the same period. (D) Comparison of GRFS probability among patients transplanted from different donors (HLA-haploidentical relative [dashed green line], HLA-identical sibling [continuous blue line], and UD [dotted red line]) during the same period. MUD, matched unrelated donor; SIB, HLA-identical sibling.

Outcomes of TCRαβ/CD19-depleted haplo-HSCT and comparison with transplants from HLA-identical sibling and MUD. (A) LFS probability according to the use of TBI in the conditioning regimen (yes, continuous blue line; no, dotted red line). (B) LFS probability according to NK alloreactivity (evaluated using the KIR-KIR-L model of prediction) (yes, dotted red line; no, continuous blue line). (C) Comparison of LFS probability among patients transplanted from different donors (HLA-haploidentical relative [dashed green line], HLA-identical sibling [continuous blue line], and UD [dotted red line]) during the same period. (D) Comparison of GRFS probability among patients transplanted from different donors (HLA-haploidentical relative [dashed green line], HLA-identical sibling [continuous blue line], and UD [dotted red line]) during the same period. MUD, matched unrelated donor; SIB, HLA-identical sibling.

Close Modal

or Create an Account

Close Modal
Close Modal